A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 6/21/2017 |
| Start Date: | January 12, 2017 |
| End Date: | May 22, 2017 |
Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects
The purpose of this study is to evaluate the effect of lanabecestat on rosuvastatin. The
amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken
with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be
measured. Information about any side effects that may occur will also be collected.
Participants will be on study for 21 days with a follow-up at least 7 days afterwards.
Screening will be undertaken within 45 days prior to enrollment.
amount of rosuvastatin in the blood will be compared, when taken alone, and then when taken
with lanabecestat. The amount of lanabecestat that gets into the bloodstream will be
measured. Information about any side effects that may occur will also be collected.
Participants will be on study for 21 days with a follow-up at least 7 days afterwards.
Screening will be undertaken within 45 days prior to enrollment.
Inclusion Criteria:
- Women not of childbearing potential may participate and include those who are:
- Infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy,
or tubal ligation), congenital anomaly such as mullerian agenesis; or
- Postmenopausal - defined as women over 50 years of age with an intact uterus who
have not taken hormones or oral contraceptives within 1 year, who have had
either Spontaneous cessation of menses for at least 12 consecutive months, or 6
to 12 months of spontaneous amenorrhea with follicle-stimulating hormone level
greater than (>)40 milli-international units per millilitre (mIU/mL) consistent
with menopause
- Caucasian and may be of Hispanic ethnicity
- Body mass index (BMI) of 19 to 32 kilogram per meter square (kg/m²), inclusive, at
the time of screening
Exclusion Criteria:
- Have a clinically significant abnormal blood pressure or heart rate (supine) as
determined by the investigator
We found this trial at
1
site
Daytona Beach, Florida 32117
Principal Investigator: Melanie Fein
Phone: 386-257-5717
Click here to add this to my saved trials
